Strattera (atomoxetine): A Guide for ADHD and Anxiety
What it is
A selective norepinephrine reuptake inhibitor (NRI). The first non-stimulant medication FDA-approved for ADHD (2002). Not a controlled substance and has no abuse potential. Available as generic atomoxetine and brand-name Strattera, in 10, 18, 25, 40, 60, 80, and 100 mg capsules.
How it works
Increases norepinephrine in the prefrontal cortex, the brain region that runs executive function (focus, planning, working memory, impulse control, and top-down regulation of emotional reactivity). Unlike stimulants, it does not directly increase dopamine in the brain's reward circuit, which is why it has no abuse potential.
Stimulants work the day you take them and wear off in 4-12 hours. Strattera works gradually and provides 24-hour coverage with no peak-and-crash pattern.
Timeline of effect
Weeks 1-2: Side effects often appear. Therapeutic effect typically not yet present.
Weeks 3-4: Side effects often settle. Early benefits may emerge.
Weeks 6-8: Full therapeutic effect, if the medication is going to work.
This slow onset is the most common reason people stop the medication prematurely. A fair trial requires reaching the target dose and staying on it for at least 6-8 weeks.
What it feels like
Strattera works subtly (which is often a benefit for anxiety and trauma). Most people describe it as a gradual lowering of internal noise rather than a noticeable "on" feeling. It does not produce the bright, motivated, suddenly-focused effect that some people experience on stimulants. The most common descriptions are things like "the static is quieter," "I'm less reactive," "I can let things go more easily," or "my mind isn't bouncing around the way it used to."
For anxiety, the feel is closer to an SSRI than to a benzodiazepine. Not sedating. No immediate calm. The baseline level of physiological tension and reactivity gradually settles over weeks. Some people don't realize it's working until they stop and feel the difference return. Others reach the target dose, finish 8 weeks, and feel no meaningful change. Both outcomes happen.
Often, the people around you notice the change before you do.
Effect on ADHD
FDA-approved for ADHD in children, adolescents, and adults.
The average effect on ADHD symptoms in adults is approximately 0.4 on the standard measure (Cohen's d), compared to 0.7-1.0 for stimulants.
A note on effect sizes: Effect size is a way of quantifying how much a treatment helps compared to placebo. By convention, 0.2 is small, 0.5 is moderate, and 0.8 is large. An effect size of 0.4 means the average person on Strattera improves more than about two-thirds of people on placebo. An effect size of 0.8 means improvement greater than roughly 80%. Stimulants average a larger effect, but averages obscure individual variation: many people respond well to Strattera and only modestly to stimulants, and vice versa.
What Strattera tends to help with:
Sustained attention and follow-through
Internal restlessness and difficulty settling
Impulsivity and reactivity
24-hour coverage (mornings, evenings, weekends without a "wear-off")
What it helps less with:
The acute "I can sit down and start the task" activation that stimulants provide
Stimulant-style cognitive sharpness or motivation
Strattera is especially useful when:
Stimulants worsen anxiety, irritability, appetite, or sleep
There is a personal or family history of substance use disorder
There is a comorbid tic disorder
24-hour coverage matters (parenting, complex evenings, weekend functioning)
A non-controlled medication is strongly preferred
Effect on anxiety
Strattera is off-label for anxiety, but the clinical picture is more interesting than the FDA labeling suggests. The evidence breaks down by population.
Adult evidence:
Adler et al., 2009 (Depression and Anxiety). The largest trial: 442 adults with ADHD and comorbid social anxiety disorder, 14 weeks, randomized double-blind placebo-controlled. Industry-sponsored (Eli Lilly). Atomoxetine improved both ADHD symptoms (effect size 0.47) and social anxiety symptoms, with a significant reduction on the Liebowitz Social Anxiety Scale (the standard SAD measure). Trait anxiety (baseline anxiety level) also improved; state anxiety (acute, in-the-moment anxiety) did not.
Ravindran et al., 2009. Tested atomoxetine in adults with social anxiety disorder alone, without ADHD. The trial was small (~26 patients) and negative: no significant benefit over placebo. This is one of the reasons SSRIs remain first-line for anxiety without ADHD.
Pediatric evidence:
Geller et al., 2007 (J Am Acad Child Adolesc Psychiatry). Found atomoxetine improved both ADHD and anxiety symptoms in children and adolescents with comorbid ADHD + anxiety.
A 2022 systematic review (Pozzi et al.) of four pediatric studies concluded that atomoxetine does not worsen anxiety and often improves it in the ADHD + anxiety population.
Practical takeaway:
For adults with ADHD and comorbid anxiety (especially social anxiety), Strattera has reasonable evidence for helping both, with the strongest support coming from a single large industry-funded RCT.
For adults with social anxiety disorder alone without ADHD, the one published trial (Ravindran et al., 2009, n ≈ 28) was negative: no benefit over placebo. For other anxiety disorders alone in adults - generalized anxiety, panic, OCD, PTSD - there are no published randomized trials, so the evidence is absent for anxiety rather than negative. SSRIs remain the better-studied first choice.
Where SSRIs are still better, regardless of ADHD status:
Panic disorder
OCD
Severe generalized anxiety where the dominant feature is worry rather than physiological reactivity
PTSD
The mechanism plausibly underlying the anxiety benefit: norepinephrine in the prefrontal cortex strengthens top-down regulation of the limbic system. This is different from stimulants, which can amplify peripheral sympathetic activity (the heart-racing, jittery feel that worsens anxiety in some people).
What patients actually report experiencing
Trial data tells you averages. Patient-reported reviews on drugs.com, WebMD, AskAPatient, and ADHD forums add texture. Themes that come up repeatedly:
The cascade effect. Many people describe the anxiety reduction as indirect at first: "my anxiety dropped because I wasn't constantly anxious about losing focus, forgetting things, falling behind." When the ADHD-driven failures stop, so does the anxiety they generate. This may be the most common pattern.
Obsessive or racing thoughts settling. "My mind isn't bouncing around with a thousand thoughts." "Obsessive thoughts - gone." Shows up more often in reviews than reduction in classic worry.
Doesn't feel "medicated." A frequent contrast with stimulants and SSRIs: "I still feel like myself, just less reactive" rather than feeling altered, flat, or wired.
The patience requirement. Almost every positive review mentions weeks 1-2 feeling bad (nausea, fatigue, sometimes a brief anxiety bump) and benefit emerging at week 3-6. People who quit early miss the response.
The bimodal response. Reviews skew bimodal: it works really well, or it's intolerable. The middle ("eh, it kind of works") is less common than with SSRIs or stimulants.
A minority of people get worse anxiety. About 9% of drugs.com reviewers tag anxiety as a side effect. For some this is an initial bump that settles; for others it persists and is the reason they stop.
A practical check at the 6-week mark (give it time): is my baseline anxiety lower than before I started, and are the situations that used to spike my anxiety still spiking it as hard? If both answers point toward improvement, it's working. If neither does, it probably isn't.
Choosing Strattera vs. the alternatives
vs. Stimulants (methylphenidate, amphetamine): Stimulants are faster (effective day one) and stronger for ADHD (effect size 0.7-1.0). They can worsen anxiety, irritability, and sleep. They are controlled substances with abuse potential. Strattera is slower, gentler, often better tolerated by anxious patients, and not controlled. Choose a stimulant when ADHD is the dominant problem and anxiety is mild or absent. Choose Strattera when anxiety is prominent, a gentler approach is preferred, stimulants have been intolerable, there is substance use history, or 24-hour coverage matters more.
vs. Nonstimulants - Guanfacine ER (Intuniv) or Clonidine ER (Kapvay): Alpha-2 agonists. FDA-approved in the US only for ADHD in children and adolescents; adult use in the US is off-label and based largely on extrapolation from pediatric data, with one Japanese phase 3 RCT supporting adult efficacy (Japan approved guanfacine ER for adults in 2019). Useful for emotional dysregulation and rejection sensitivity, irritability, hyperarousal, and sleep. Can be particularly helpful for trauma physiology. Tend to be sedating (especially clonidine), create exercise intolerance (can improve), and can lower blood pressure (causing lightheadedness or falls if standing too quickly and not drinking water). Modest effect on attention compared to Strattera or stimulants. Often used in combination with a stimulant when irritability or emotional reactivity is prominent. Choose guanfacine when emotional reactivity, irritability, or sleep problems are the dominant features. Choose Strattera when attention and focus are the priority and you want a single medication for both ADHD and anxiety.
vs. Nonstimulants - Qelbree (viloxazine): An NRI in the same broad mechanism class as Strattera. FDA-approved for ADHD in children (2021) and adults (2022). No generic available yet, so it is expensive (often $400+/month without insurance), and most insurance plans require prior authorization documenting failure of 1-2 prior ADHD medications before they'll cover it. The clinical profile is similar to Strattera with some differences: possibly faster onset (effect within 1-2 weeks in some trials, versus 4-6 weeks for Strattera), possibly lower rates of sexual side effects, but much less long-term data. Reasonable to consider when Strattera was partially helpful but poorly tolerated, or when Strattera's specific side effects were the limiting factor.
vs. Nonstimulants - Bupropion (Wellbutrin): An NDRI antidepressant used off-label for ADHD. Generic and inexpensive. Modest effect on ADHD symptoms, smaller than Strattera. Activating, often useful for the motivation/energy piece of ADHD. Can worsen anxiety in some people (especially the immediate-release formulation), which makes it a less natural fit than Strattera when anxiety is prominent. Lowers seizure threshold, so contraindicated with active eating disorders, frequent vomiting, binge-drinking, or seizure history. Choose bupropion when there is comorbid depression alongside ADHD, when stimulants and Strattera have failed or aren't appropriate, or when the motivational/energy aspects of ADHD are the priority and anxiety isn't a major feature.
vs. SSRIs (sertraline, escitalopram, fluoxetine): First-line for anxiety alone. No direct ADHD effect. Take 4-6 weeks for anxiety benefit, a similar slow timeline to Strattera. A common alternative is SSRI + stimulant: better ADHD control plus dedicated anxiety treatment, two medications instead of one. No combo-pills exist. Choose this combination when ADHD is severe enough that stimulant-strength coverage is needed and anxiety is severe enough to warrant its own treatment. Choose Strattera alone when you want a single medication, when stimulants are not a good fit, or when anxiety and ADHD are both moderate.
vs. Buspirone: A 5HT1A partial agonist. Modest anxiolytic effect, takes weeks to build. No ADHD effect. Sometimes used as an add-on for residual anxiety. Not a strong stand-alone option for either condition.
Combination approaches that are commonly used:
Strattera + stimulant (for partial Strattera response; evidence is limited but the combination is used)
Strattera + SSRI (less common but acceptable; SSRI selection matters because of CYP2D6 interactions, see below)
Strattera + alpha-2 agonist (guanfacine or clonidine; both non-stimulant, complementary mechanisms - Strattera for attention, alpha-2 for emotional reactivity and sleep)
Strattera + bupropion (used rarely; bupropion is a strong CYP2D6 inhibitor and raises Strattera levels significantly, so Strattera dose needs to be reduced)
Stimulant + SSRI (most common pairing for ADHD + anxiety)
Stimulant + guanfacine (for ADHD + emotional reactivity or sleep)
Stimulant + bupropion (used occasionally when there's comorbid depression and the stimulant alone isn't covering mood)
Dosing
Starting dose (adults): 40 mg once daily for 7 days
However, I work with a lot of sensitive, anxious, and trauma-physiology folks. I often start at 10 or 18mg.
Target dose: 80 mg once daily
Maximum dose: 100 mg/day
Can be taken once daily in the morning, or split (morning + early afternoon) if side effects are bothersome
Take with food if nausea occurs (a small snack is enough)
About 7% of people of European ancestry (varying percentages in other populations) are CYP2D6 poor metabolizers, a genetic variation in how the liver processes the medication. They reach higher blood levels at standard doses and may only need 40 mg/day as the target dose. Genetic testing is available if side effects are disproportionate, usually $330 for most people with insurance - however, usually doesn’t add much more information than what you can infer.
Side effects
Common (usually transient, often resolve within 2-3 weeks):
Nausea (most common; take with food)
Decreased appetite, mild weight loss
Fatigue or sedation
Dry mouth
Mild increase in heart rate (~5-7 bpm) and blood pressure (~3-5 mmHg)
Common but under-discussed:
Sexual side effects, primarily in adult males. In placebo-controlled adult trials: erectile dysfunction in 7-8% vs ~2% on placebo, decreased libido in ~5% vs ~3% on placebo, ejaculation disorders in ~3% vs ~1% on placebo. Rates in adult females are similar to placebo. The FDA label notes these numbers are likely underestimates because patients and clinicians underreport sexual side effects. Onset is usually within the first 2 weeks; median time to resolution is 3-8 weeks even with continued treatment, so the effects often improve without stopping the medication. Worth raising with your clinician if it persists.
Urinary hesitancy or difficulty initiating urination, more common in men, especially those with prostate issues.
Rare but serious. Contact your clinician right away:
Hepatotoxicity: yellowing of skin or eyes, dark urine, right upper abdominal pain, or flu-like symptoms without an actual infection. Very rare (a handful of cases in millions of prescriptions), but the medication should be stopped immediately if suspected.
Suicidal ideation: the FDA black box warning is based on data primarily in children and adolescents. Risk in adults appears low but real, especially in the first weeks of treatment or after dose changes.
Allergic reaction: rash, hives, swelling of face/lips/tongue.
Cardiovascular: chest pain, fainting, palpitations.
Drug interactions
Contraindicated:
MAOIs (phenelzine, tranylcypromine, selegiline, isocarboxazid). Must be separated by at least 2 weeks.
Requires dose adjustment:
Strong CYP2D6 inhibitors: fluoxetine, paroxetine, bupropion. These raise atomoxetine blood levels significantly. Combination is not contraindicated but Strattera dose typically needs to be reduced.
SSRIs with minimal CYP2D6 effect (escitalopram, sertraline, citalopram) are cleaner choices when combining Strattera with an SSRI.
Monitor:
Beta-agonists (albuterol, other inhalers): may amplify cardiovascular effects.
Cost and coverage
Generic atomoxetine is widely available and substantially cheaper than brand-name Strattera:
Generic atomoxetine with GoodRx or SingleCare coupon: approximately $15-50 for a 30-day supply
Generic atomoxetine cash price (no coupon): approximately $120-300 for a 30-day supply
Brand-name Strattera: approximately $400+ for a 30-day supply
Generic atomoxetine is on most commercial insurance and Medicare Part D formularies, usually as a Tier 2 (preferred generic). Some plans require prior authorization or step therapy (documentation that a stimulant was tried first or is contraindicated), particularly for adults. Cost Plus Drugs (costplusdrugs.com) and pharmacy discount cards can be useful when insurance coverage is limited.
If it doesn't work
An adequate trial is 80 mg/day for 6-8 weeks at minimum. If there is no meaningful benefit after that, the options are:
Switch to a stimulant. Most people who don't respond to Strattera respond to a stimulant, given the larger average effect size for ADHD.
Switch to or add guanfacine ER. Particularly useful if emotional reactivity, irritability, or sleep difficulty was prominent.
Add or switch to an SSRI. If anxiety turns out to be the dominant problem, an SSRI alone or SSRI + stimulant often works better.
Try combination therapy. Strattera + stimulant is sometimes used when there is partial Strattera response.
Reassess the diagnosis. Sleep apnea, depression, trauma, thyroid dysfunction, and substance use can mimic or worsen ADHD and anxiety. A poor medication response is a reasonable trigger for re-evaluation.
Consider non-medication approaches. CBT for ADHD, ADHD coaching, exercise, sleep optimization, and treatment of contributing factors often add meaningful benefit alongside or instead of medication.
Practical notes
Missed dose: skip it. Do not double up.
Stopping: no taper required. Unlike SSRIs, Strattera has no discontinuation syndrome. Discuss with your clinician before stopping if it has been helping.
Capsules: swallow whole. Do not open or crush. The powder is an eye irritant.
Pregnancy: limited safety data. If you are pregnant, planning pregnancy, or breastfeeding, discuss with your clinician. The National Pregnancy Registry for ADHD Medications (866-961-2388) collects safety data.
Monitoring
Baseline blood pressure and heart rate before starting
Periodic BP/HR checks during treatment
Liver function tests only if symptoms suggest hepatic involvement (routine LFTs not required)
Mood and suicidality, particularly in the first 4-8 weeks and after dose changes
Weight, especially in adolescents
When to call
Yellowing of skin or eyes, dark urine, RUQ pain, or unexplained flu-like symptoms
New or worsening suicidal thoughts or significant mood changes
Rash, hives, or facial/throat swelling
Chest pain, fainting, or irregular heartbeat
Side effects that have not faded by week 4 or are interfering with daily functioning
If you're an expert in ADHD and anxiety and have thoughts, corrections, or want to contribute, please reach out: drpop@patriciapopmd.com.